Children's National Medical Center

University System of Maryland

Children's Research Institute, Children's National Medical Center

Anthony Sandler

Peter Kofinas

Catherine M Bollard

Raymond W Sze

Adam Michael Behrens

Steven L Zeichner

Rohan Fernandes

Matthieu F Dumont

Conrad Russell Y Cruz

Juliana Cano-mejia

Rachel Burga

Elizabeth E Sweeney

Katherine Davenport

Lina Chakrabarti

Claire Fraser

Emmanuel Mongodin

Michael Sikorski

Priya Srinivasan

Hope Jackson

Nora Lee

Combination treatment with Prussian blue nanoparticles and at least one immunotherapeutic treatment. Stable, functionalized Prussian blue nanoparticles, including those with enhanced stability under alkaline conditions, and methods of cancer, neoplasm, and tumor treatment using them, including photothermal treatment and combination immunotherapeutic treatments.

Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof

A method for determining a likelihood of appendicitis in a subject is disclosed. The method comprises the steps of (a) determining the relative abundance of microorganisms corresponding to one or more operational taxonomic units (OTUs) in a test biological sample obtained from the subject; (b) comparing the relative abundance of the microorganisms in each of the one or more OTUs to a corresponding reference value assigned to each of the one or more OTUs, and (c) determining a likelihood of appendicitis in the subject based on the result in step (b), wherein a significant increase in relative abundance of the microorganisms in the one or more OTUs indicates a high risk of appendicitis in the subject. Also disclosed is a kit for determining a likelihood of appendicitis in a subject.

Compositions and methods for determining the likelihood of appendicitis

ID Protein targeted cancer immunotherapy. The invention provides a cell-based attenuated live tumor cell vaccine that safely produces broad cellular tumor-specific immunity, protects against tumor formation in prophylactic tumor models, and in combination with the clinically relevant immune modulator s such as antibodies to CTLA-4 or antibodies to PD-L1 can destroy established tumors in mammals.

Id-protein targeted tumor cell vaccine

Compositions comprising biomedical polymers, and in particular unique blends of poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) are provided. Methods of forming polymer fibers using such compositions and solution blow spinning techniques are also provided, as well as methods of delivering the blow spun polymer fibers onto a surface (e.g., such as tissue for use as a surgical scaffold, sealant or tissue adhesive).

Solution blow spun polymer fibers, polymer blends therefor and methods and use thereof

Growing community of inventors

Bethesda, MD, United States of America

Anthony Sandler